Rubnitz JE, Lacayo NJ, Inaba H, et al. - Researchers introduced clofarabine into the first course of remission induction among children with acute myeloid leukemia to find an effective and less toxic therapy and to reduce exposure to daunorubicin and etoposide. They enrolled 285 patients at eight centers from 2008 through 2017; random assignment of 262 to receive clofarabine and cytarabine (Clo+AraC, n = 129) or high-dose cytarabine, daunorubicin, and etoposide (HD-ADE, n = 133) as induction I was performed. Outcomes suggest the possibility of a reduced requirement for anthracycline and etoposide in pediatric patients with acute myeloid leukemia, in addition, to reduced rates of cardiomyopathy and treatment-related cancer in correlation to using clofarabine with cytarabine during remission induction.